English 
Japanese 
April 21, 2024
Announcement of setting the record date for stock split
Announcement of setting the record date for stock split（pdf）
Read More
January 24, 2024
PRISM BioLab raises 1.5 billion yen in Series C fundraising to advance technologies and programs targeting protein-protein interactions
TOKYO, Japan, 24 Jan 2024: –PRISM BioLab, Co. Ltd. , a leading discovery and development biotechnology...
Read More
November 28, 2023
PRISM BioLab and Lilly Enter into a Drug Discovery Collaboration on a Protein-Protein Interaction Target
TOKYO, Japan, 28 Nov 2023: –PRISM BioLab, Co. Ltd. , a leading discovery and development biotechnology...
Read More
May 31, 2023
PRISM BioLab announces a milestone achievement based on the license agreement with Ohara Pharmaceutical
TOKYO, Japan, 31 May 2023: – PRISM BioLab, a Japan based biotechnology company with a proprietary...
Read More
January 13, 2023
New study by PRISM Biolab demonstrates rational design of small molecule inhibitors of CTLA-4 and B7-1 protein-protein interaction utilizing only a sequence of a binding peptide
The paper published in the special issue of Pharmaceuticals journal dedicated to “Small Molecules Targeting Protein-Protein...
Read More
October 28, 2022
Pharma Intelligence Award Japan 2022 Commemorative Webinar “PPI Inhibition by Small Molecules: A New Drug Discovery Paradigm”
PRISM BioLab's proprietary drug discovery platform, PepMetics®, is a technology that enables the control of protein-protein...
Read More
September 1, 2022
PRISM Biolab Wins Biotech Company of the Year Award of Informa Pharma Intelligence Award 2022
We are pleased to announce that we have won the Biotech company of the year in...
Read More
January 5, 2022
PRISM BioLab, enters multi-project drug discovery collaboration with Roche and Genentech
TOKYO, Japan, 5th Jan. 2022: -- PRISM BioLab, a Japan based biotechnology company with a proprietary...
Read More
November 1, 2021
The CREB-binding protein (CBP)/β-catenin inhibitor E7386, co-created by Eisai and PRISM BioLab, achieved the clinical POC (Proof of Concept)
Eisai Co., Ltd. and PRISM BioLab Co., Ltd. announced today that the CREB-binding protein (CBP) /...
Read More
November 1, 2021
PRISM BioLab raised 100 million yen in Series C funding from Eisai
PRISM BioLab, the Japan based biotechnology company with proprietary small molecule drug discovery technology ”PepMetics®”, today...
Read More